WALTHAM, Mass. A company that develops a drug for acute migraines in pill form that doesn’t interact with patients’ vascular disease could capture almost half of the market share, according to a report by Decision Resources.
The report, released Wednesday, found that if a company were to develop such a drug, one that patients with a history, symptoms or signs of vascular disease could use, it would earn a 45% share of patients, according to a survey of U.S. neurologists. Current drugs used to treat migraines, called triptans, are known to carry a risk of cardiovascular side effects.
The report also found that the injectable Sumavel DosePro (sumatriptan), made by Zogenix, Astellas Pharma and Desitin Pharmaceuticals, will become Decision Resources’ proprietary gold standard for migraine in 2013. The drug was launched in the United States in January.